TrialNCT07481981
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
- Status
- RECRUITING
- Phase
- PHASE3
- Last update posted
- 09/04/2026
- Start
- 07/21/2026
- Sponsor
- Insmed Incorporated
- Specialties
- family-medicine, cardiology
Conditions: Pulmonary Arterial Hypertension
Brief summary
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.
Protocol documents and results are not hosted here. Verify every detail on ClinicalTrials.gov.